Physician profile
Jane Kim
NPI 1881255933
$8,656.82
in general payments reported to CMS, 2019-2025
29 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,310 · 2022: $1,821 · 2023: $1,727 · 2024: $2,052 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,505 · Education: $20.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,505.43 |
| Education | $20.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,957.34 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $1,148.92 | 2023-2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $914.68 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $583.37 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $500.71 | 2021-2024 | Entyvio |
| Genzyme Corporation | $471.70 | 2022-2025 | |
| Celgene Corporation | $286.45 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $258.59 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $184.95 | 2023 | |
| Intercept Pharmaceuticals, INC. | $154.45 | 2022-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $132.97 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $129.65 | 2022-2024 | Rebyota |
| Braintree Laboratories, INC. | $129.61 | 2022-2025 | Sutab, Suflave |
| Redhill Biopharma INC. | $123.80 | 2021-2023 | Talicia |
| Alfasigma USA, INC. | $87.55 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $86.75 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $77.83 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $71.88 | 2021-2022 | |
| Madrigal Pharmaceuticals | $70.61 | 2025 | Rezdiffra |
| Lucid Diagnostics INC. | $63.90 | 2022-2023 | |
| Celltrion USA INC. | $46.55 | 2024 | Zymfentra |
| Alnylam Pharmaceuticals INC. | $27.62 | 2022 | |
| Dexcom, INC. | $25.17 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.32 | 2023 | Cyltezo |
| Gilead Sciences, INC. | $22.85 | 2024 | |
| Fresenius Kabi USA, LLC | $20.30 | 2023 | Idacio |
| Vivus LLC | $20.14 | 2022 | |
| Phadia US INC. | $19.47 | 2023 | Immunocap |
| Ardelyx, INC. | $15.69 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.